Travere Therapeutics (TVTX) Income from Continuing Operations (2011 - 2026)
Travere Therapeutics (TVTX) posted Income from Continuing Operations of 36602000.0 for Q1 2026, down 66.48% on a QoQ basis from 21986000.0 in Q4 2025, and up 11.22% year-over-year from 32910666.35 in Q1 2025.
Travere Therapeutics (TVTX) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Travere Therapeutics' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 36602000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 11.22% year-over-year to 36602000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 45637000.0 (up 79.8% YoY) and the FY2025 annual result came in at 50261000.0, up 84.32% from the prior year.
- Income from Continuing Operations was 36602000.0 for Q1 2026 at Travere Therapeutics, down from 21986000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 25706000.0 in Q3 2025 and bottomed at 135958000.0 in Q1 2024.
- A 5-year average of 65605529.41 and a median of 80023000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 135.87% — and 2025, when it jumped 146.95%.
- Travere Therapeutics' Income from Continuing Operations stood at 85636000.0 in 2022, then dropped by 3.46% to 88596000.0 in 2023, then jumped by 31.97% to 60268000.0 in 2024, then jumped by 63.52% to 21986000.0 in 2025, then slumped by 66.48% to 36602000.0 in 2026.
- Business Quant data shows TVTX's Income from Continuing Operations at 36602000.0 in Q1 2026, 21986000.0 in Q4 2025, and 25706000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -36.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.60 Mn |
| Dec 31, 2025 | -21.99 Mn |
| Sep 30, 2025 | 25.71 Mn |
| Jun 30, 2025 | -12.76 Mn |
| Mar 31, 2025 | -41.23 Mn |
| Dec 31, 2024 | -60.27 Mn |
| Sep 30, 2024 | -54.75 Mn |
| Jun 30, 2024 | -69.65 Mn |
| Mar 31, 2024 | -135.96 Mn |
| Dec 31, 2023 | -88.60 Mn |
| Sep 30, 2023 | -89.24 Mn |
| Jun 30, 2023 | -101.93 Mn |
| Mar 31, 2023 | -96.56 Mn |
| Dec 31, 2022 | -85.64 Mn |
| Sep 30, 2022 | -84.06 Mn |
| Jun 30, 2022 | -80.02 Mn |
| Mar 31, 2022 | -81.75 Mn |
| Dec 31, 2021 | -88.77 Mn |
| Sep 30, 2021 | -35.64 Mn |
| Jun 30, 2021 | -39.01 Mn |